Videos
Choosing DMTs and Ongoing Debates in Multiple Sclerosis: Robert T. Naismith, MD
November 21st 2022The professor of neurology at Washington University in St. Louis offered an overview of the State of the Science Summit that was held on November 3, 2022, featuring a panel of expert clinicians. [WATCH TIME: 3 minutes]
The Inflation Reduction Act Leads Towards Increased Advocacy for MS: Bari Talente, JD
November 21st 2022The executive vice principal of advocacy and healthcare access at the National MS Society spoke about the implementation of the Inflation Reduction Act and how clinicians may use health navigator services to advocate for their patients with MS. [WATCH TIME: 4 minutes]
Post-Conference Perspectives and Updates in Neuropalliative Care: Benzi Kluger, MD, MS
November 21st 2022The president of the International Neuropalliative Care Society provided an overview of the organization’s recently concluded conference and the significance of the growth of neuropalliative care. [WATCH TIME: 6 minutes]
Differences in Effective Therapies for Pediatric versus Adults with MS: Brenda Banwell, MD
November 18th 2022The chief of neurology and codirector of the neuroscience Center at the Children's Hospital of Philadelphia spoke at ECTRIMS 2022 about the difference in conversation for therapies between pediatric patients and adult patients with MS. [WATCH TIME: 5 minutes]
Living an Inspirational Life With Pediatric MS: Brenda Banwell, MD
November 17th 2022The chief of neurology and codirector of the neuroscience Center at the Children's Hospital of Philadelphia spoke at ECTRIMS 2022 about how her patients with pediatric MS have been inspirational to her in her practice. [WATCH TIME: 4 minutes]
The Co-occurrence of Sleep Disorders with Other Health Conditions
November 17th 2022Wendy L. Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP, and Debra Davis, CRN, discuss the relationship between sleep disorders and other health conditions, such as cardiovascular, respiratory, and psychiatric diseases.
The Inflation Reduction Act, Lower Cost of Medications and Health Insurance for MS: Bari Talente, JD
November 16th 2022The executive vice principal of advocacy and healthcare access at the National MS Society spoke on how the Inflation Reduction Act of 2022 will impact patients with MS and what the clinical community should be aware of. [WATCH TIME: 5 minutes]
Advantages of Wellness as a Therapy for Pediatric MS: Brenda Banwell, MD
November 15th 2022The chief of neurology and codirector of the neuroscience Center at the Children's Hospital of Philadelphia, spoke about the wellbeing of pediatric patients with MS in reference to her presentation at ECTRIMS 2022. [WATCH TIME: 4 minutes]
Beginning and Transitioning DMT in MS: Dalia Rotstein, MD, MPH
November 14th 2022The assistant professor of medicine at University of Toronto, and neurologist at St. Michael's Hospital spoke about the process of changing or beginning treatment with a variety of disease-modifying therapies in multiple sclerosis. [WATCH TIME: 4 minutes]
Establishing a Proof Of Concept Model to Improve MS Treatment Optimization: Carrie Hersh, DO, MSc
November 14th 2022The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine offered insight on her presentation at ECTRIMS 2022 looking at 2-stage models to better understand heterogeneous treatment effects of MS DMTs. [WATCH TIME: 6 minutes]
The Sumaira Foundation Providing Access to Care for Patients with NMOSD: Sumaira Ahmed
November 13th 2022The founder and executive director of the Sumaira Foundation discussed her experience living with NMOSD and the global organization she created to help patients with the same condition. [WATCH TIME: 6 minutes]
Critical Takeaways, Learning Experiences From the Tofersen Trials in ALS: Timothy Miller, MD, PhD
November 11th 2022The codirector of the ALS Center at Washington University School of Medicine provided perspective on the lessons learned from the trials of tofersen, as it aims to become the first FDA-approved therapy specific to SOD1 ALS. [WATCH TIME: 4 minutes]
Progress for Patients With Pediatric MS, Fingolimod's Risk-Benefit Profile: Brenda Banwell, MD
November 11th 2022The chief of neurology and codirector of the neuroscience Center at the Children's Hospital of Philadelphia spoke about her presentation at ECTRIMS 2022 on the treatment of pediatric MS. [WATCH TIME: 5 minutes]
Role of Tofersen Among Other Previously Approved ALS Therapies: Timothy Miller, MD, PhD
November 10th 2022The codirector of the ALS Center at Washington University School of Medicine in St. Louis provided background on how tofersen would be used alongside other ALS medications if approved. [WATCH TIME: 3 minutes]
